Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes
暂无分享,去创建一个
[1] S. Rosenberg,et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] A. Trautmann,et al. Multiple survival signals are delivered by dendritic cells to naive CD4+ T cells , 2005, European journal of immunology.
[3] S. Rosenberg,et al. Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples , 2005, Journal of immunotherapy.
[4] S. Rosenberg,et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.
[5] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Richard A. Morgan,et al. Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.
[7] S. Rosenberg,et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.
[8] Pedro Romero,et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. , 2005, Immunity.
[9] S. Rosenberg,et al. Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen , 2004, Journal of immunotherapy.
[10] S. Rosenberg,et al. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] A. Melcher,et al. A simple method to cure established tumors by inflammatory killing of normal cells , 2004, Nature Biotechnology.
[12] B. Chauffert,et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.
[13] A. Simpson,et al. The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.
[14] P. Cresswell,et al. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids , 2004, Immunogenetics.
[15] S. Rosenberg,et al. High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.
[16] Yao-Tseng Chen,et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] Yao-Tseng Chen,et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.
[18] Yao-Tseng Chen,et al. A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. , 2002, Gene.
[19] A. Lokshin,et al. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. , 2002, International immunology.
[20] Yao-Tseng Chen,et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Sidney,et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. , 2002, Cancer research.
[22] F. Marincola,et al. A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.
[23] V. Brusic,et al. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. , 2002, Cancer research.
[24] T. Schumacher,et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[25] E. Shevach,et al. Control of T‐cell activation by CD4+ CD25+ suppressor T cells , 2001, Immunological reviews.
[26] F. Marincola,et al. Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.
[27] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[28] S. Rosenberg,et al. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[29] S. Matsushita,et al. Monocytes Are Differentially Activated Through HLA-DR, -DQ, and -DP Molecules Via Mitogen-Activated Protein Kinases1 , 2001, The Journal of Immunology.
[30] U. Grohmann,et al. Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo1 , 2000, The Journal of Immunology.
[31] D. Jäger,et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. H. van der Burg,et al. Importance of CD4(+) T helper cell responses in tumor immunity. , 2000, Immunology letters.
[33] E. Bröcker,et al. MHC class II and CD40 play opposing roles in dendritic cell survival , 2000, European journal of immunology.
[34] S. Rosenberg,et al. Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules , 2000, The Journal of Immunology.
[35] D. Jäger,et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] N. Restifo,et al. Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen , 2000, The Journal of Immunology.
[37] G. Plautz,et al. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. , 2000, Critical reviews in immunology.
[38] Jonathan J. Lewis,et al. Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.
[39] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[40] A. Ohta,et al. Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.
[41] D. Jäger,et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. , 1999, International journal of cancer.
[42] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[43] B. Moss,et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[44] S. Rosenberg,et al. A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.
[45] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[46] Spyros A. Kalams,et al. The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.
[47] L. Michaux,et al. LAGE‐1, a new gene with tumor specificity , 1998, International journal of cancer.
[48] D. Jäger,et al. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.
[49] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[50] G. Schuler,et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 [published erratum appears in J Exp Med 1996 Oct 1;184(4):following 1590] , 1996, The Journal of experimental medicine.
[51] R. Steinman,et al. Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.
[52] S. Rosenberg,et al. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.
[53] R. North. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.
[54] R. Gershon. A Disquisition on Suppressor T Cells , 1975, Transplantation reviews.